Gupta M., Paul S, Kajil M., Ostrovski I., Tsigoulis M., Verma S., Singh N. Acetylsalicilic acid use in Primary Prevention in Canada: Insight from the Primary Care Audit of Global Risk Management (PARADIGM) Study. Curr Res Cardiol. 2016;3(3):67-70

Gupta M., Tsigoulis M., Kajil M., Verma S., Singh N. Audit of cardiovascular risk assessment and lipid management by Canadian primary care physicians. Curr Res Cardiol. Summer 2016; Vol 3 No 2: 33-37.


Law TK., MD, Yan AT., Gupta A., Kajil M., Tsigoulis M., Singh N., Verma S., Gupta M. Primary Prevention of Cardiovascular Disease: Global Cardiovascular Risk Assessment and Management in Clinical Practice. European Heart Journal - Quality of Care and Clinical Outcomes; published online June 2 2015

Andrew C.T. Ha, Narendra Singh,  Jafna L. Cox, G.B. John Mancini, Paul Dorian, Carl Fournier, David J. Gladstone, Evan Lockwood,  Ashfaq Shuaib,  Mahesh Kajil, Michelle Tsigoulis, Milan Gupta Patterns of oral anticoagulant use for stroke prevention in contemporary Canadian atrial fibrillation practice - insights from the Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) registry; Canadian Journal of Cardiology; May 03, 2015, Vol. 32(2), 204-210

Gupta M., Smitzko P., Singh N., Tsigoulis M., Kajil M., Stone J. Management and Control of Uncomplicated Hypertension in Canada: Insight from the Primary Care Audit of Global Risk Management (PARADIGM) Study. Can J Cardiol; May 2015, Vol. 31(5), 664-670


Everett BM., Pradhan AD., Solomon DH., Paynter N., Macfadyen J., Zaharris E., Gupta M., Clearfield M., Libby P., Hasan AA., Glynn RJ., Ridker PM. Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166:199-207 e115.


Gupta M., Teoh H., Tisgoulis M., Quan A., Braga MFB., Verma S. The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients. Experimental and Clinical Cardiology. Winter 2012, Volume 17 Issue 4: 191-196.

Verma S., Gupta M., Ridker P. Therapeutic Targeting of Inflammation in Atherosclerosis: We Are Getting Closer. Can J Cardiol. 2012 Dec; 28 (6): 619-622.

Gupta M, Singh N, Tsigoulis M, Kajil M, Hirjikaka S, Quan A, Teoh H and Verma S. Perceptions of Canadian Primary Care Physicians Towards Cardiovascular Risk Assessment and Lipid Management. Can J Cardiol. 28 (2012) 14-19.


Mancini J.G.B, Baker S., Bergeron J., Fitchett D., Frohlich J., Genest J., Gupta M., Hegele R., Ng D. and Pope J. Diagnosis, prevention and management of statin adverse effects and intolerance: Proceedings of a Canadian working group consensus conference. Can J Cardiol. 27 (2011) 635-662.

Bainey K., Norris C., Gupta M., Southern D., Galbraith D., Knudtson M.L, and Graham M. Altered health status and quality of life in South Asians with coronary artery disease. Alberta and Brampton, Ontario Am Heart J. 2011; 162:501-6.

Gupta M, Martineau P, Tran T, Despres J-P, Gaw A, De Teresa E, Farsang C, Gensini G.F, Leiter L, Blanco-Colio L.M, Egido J, Langer A. Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European Origin: insights from the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. J Clin Pharmacol May 24, 2011. 0091270011407196.

Leiter L, Fitchett D, Gilbert R, Gupta M, Mancini J, McFarlane P, Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox J, Despres J-P, Genest J, Harris S, Lau D, Lewanczuk R, Liu P, Lonn E, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin S, Sharma AM, Steele A, Stone J, Tardif J-C, Tobe S, Ur E. Indentification and management of cardiometabolic risk in Canada. Detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol. 27(2011) cl-c33.

Grace S.L., Russell K.*, Reid R., Oh P., Anand S., Rush J., Williamson K., Gupta M., Alter D.A., and Stewart D. E. Effect of cardiac rehabilitation referral stratedgies on utilization rates: A prospective, controlled study. Archives of Internal Medicine, 2011: 171(3), 235-241. February.


Shukla PC, Singh KK, Yanagawa B, Teoh H, Verma S. DNA Damage Repair and Cardiovascular Diseases. JCVP 2010;56:241-245

Szmitko PE, Leiter LA, Verma S. The incretin system and cardiometabolic disease. Can J Cardiol 2010: 26: 87-95.

Gupta M., Szmitko P.E., Tsigoulis M., Braga M., Kajil M., Hirjikaka S., Quan A., Teoh H. and Verma S: Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. JCVP 2010 Sep;56(3): 241-5


Verma S, Mesana TG. Mitral-valve repair for mitral-valve prolapse. N Engl J Med 2009: 361: pp 2261-9.

Fitchett D, Eikelboom J, Fremes A, Mazer S, Singh A, Bittira B, Brister A, Graham JJ, Gupta M, Karkouti K, Lee A, Love M, McArthur R, Peterson M, Verma S, Yau, TM. Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. Can J Cardiol: 2009: 25(12): pp 683-9.

Badiwala MV. Verma S, Rao S. Surgical Management of Ischemic Mitral Regurgitation. Circulation: 2009: 120(13): pp 1287-93.

Philpott AC, Lonn E, Title LM, Verma S, Buithieu J, Charbonneau F, Anderson TJ.
Comparison of new measures of vascular function to flow mediated dilatation as a measure of cardiovascular risk factors. Am J Cardiol. 2009 Jun 1;103(11):1610-5.

Chan CT, Lovren F, Pan Y, Verma S. Nocturnal haemodialysis is associated with improved vascular smooth muscle cell biology. Nephrol Dial Transplant. 2009: 24(12): pp 3867-71.

Kuo LT, Chen SJ, Cherng WJ, Yang NI, Lee CC, Cheng CW, Verma S, Wang CH.
Late reperfusion of a totally occluded infarct-related artery increases granulocyte-colony stimulation factor and reduces stroma-derived factor-1alpha blood levels in patients with ongoing ischemia after acute myocardial infarction. Int Heart J. 2009 Jul;50(4):433-44.

Verma S, Lonn EM, Nanji A, Browne K, Ward R, Robertson A, Conradson H, Hildebrand K, Brant R, Anderson TJ. Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results. Can J Cardiol. 2009 Jul;25(7):e236-40.

Gupta M, Braga MF, Teoh H, Tsigoulis M, Verma S. Statin effects on LDL and HDL cholesterol in South Asian and white populations. J Clin Pharmacol. 2009 Jul;49(7):831-7.

Lovren F, Pan Y, Shukla PC, Quan A, Teoh H, Szmitko PE, Peterson MD, Gupta M, Al-Omran M, Verma S. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab. 2009 Jun;296(6):E1440-9.

Desjardins JF, Pourdjabbar A, Quan A, Leong-Poi H, Teichert-Kuliszewska K, Verma S, Parker TG. Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction. Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1457-65.

Yan RT, Yan AT, Anderson TJ, Buithieu J, Charbonneau F, Title L, Verma S, Lonn EM. The differential association between various anthropometric indices of obesity and subclinical atherosclerosis. Atherosclerosis. 2009 Apr 16. [Epub ahead of print]

Jialal I, Verma S, Devaraj S. Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. Clin Chem. 2009 Feb;55(2):206-8.


Title LM, Lonn E, Charbonneau F, Fung M, Mather KJ, Verma S, Anderson TJ. Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome. Vasc Med. 2008 Nov;13(4):263-70.

Gupta M, Braga MB, Verma S. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. Can J Cardiol. 2008 Oct;24(10):e65-9.

Kuo LT, Yang NI, Cherng WJ, Verma S, Hung MJ, Wang SY, Liu MH, Chen SY, Wang CH. Serum interleukin-6 levels, not genotype, correlate with coronary plaque complexity. Int Heart J. 2008 Jul;49(4):391-402.

Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, Levitt KS, Oudit GY, Al-Omran M, Stewart DJ, Slutsky AS, Peterson MD, Backx PH, Penninger JM, Verma S. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1377-84.

Verma S, Gupta MK. Aliskiren improves nitric oxide bioavailability and limits atherosclerosis. Hypertension. 2008 Sep;52(3):467-9.

Teoh H, Quan A, Bang KW, Wang G, Lovren F, Vu V, Haitsma JJ, Szmitko PE, Al-Omran M, Wang CH, Gupta M, Peterson MD, Zhang H, Chan L, Freedman J, Sweeney G, Verma S. Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab. 2008 Sep;295(3):E658-64.

Teoh H, Quan A, Bang KW, Wang G, Lovren F, Vu V, Haitsma JJ, Szmitko PE, Al-Omran M, Wang C-H, Gupta M, Peterson MD, Zhang H, Chan L, Freedman J, Sweeney G, Verma S. Adiponectin deficiency promotes endothelial activation and profoundly impairs survival in murine models of inflammation and sepsis. Am J Physiol: 2008: 52(3): pp E658-E664.

Al-Omran M, Mamdani MM, Lindsay TF, Melo M, Juurlink DN, Verma S; Systematic Assessment of Vascular Risk Investigators. Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study. J Vasc Surg. 2008 Sep;48(3):607-12.

Szmitko PE, Verma S.The endocannabinoid system and cardiometabolic risk.Atherosclerosis. 2008 Aug;199(2):248-56.

Teoh H, Quan A, Lovren F, Wang G, Tirgari S, Szmitko PE, Szalai AJ, Ward ME, Verma S.Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis. 2008 Dec;201(2):318-25.

Kim BO, Verma S, Weisel RD, Fazel S, Jia ZQ, Mizuno T, Li RK. Preservation of heart function in diabetic rats by the combined effects of muscle cell implantation and insulin therapy. Eur J Heart Fail. 2008 Jan;10(1):14-21.

Wang CH, Cherng WJ, Yang NI, Hsu CM, Yeh CH, Lan YJ, Wang JS, Verma S. Cyclosporine increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. Am J Physiol Regul Integr Comp Physiol. 2008 Mar;294(3):R811-8.


Teoh H, Verma S. C-reactive protein, metabolic syndrome, and end organ damage. Metabolism. 2007 Dec;56(12):1620-2.

Gupta M, Verma S, Mancini GB. ACE inhibitors: back to prime time? Heart. 2007 Sep;93(9):1015-6.

Teoh H, Quan A, Verma S. Does C-reactive protein predict saphenous vein graft patency? J Thorac Cardiovasc Surg. 2007 Aug;134(2):277-9.

Szmitko PE, Verma S. C-reactive protein and reendothelialization: NO involvement. Circ Res. 2007 May 25;100(10):1405-7.

Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol. 2007 Apr;292(4):H1655-63. Review.

Verma S, Slutsky AS. Idiopathic pulmonary fibrosis--new insights. N Engl J Med. 2007 Mar 29;356(13):1370-2.

Teoh H, Lovren F, Verma S. Vascular dysfunction: a Janus face of visfatin in diabetes? Metabolism. 2007 Apr;56(4):459-61.

Verma S, Feindel CM. Skeletonized internal thoracic arteries for CABG surgery: a new gold standard? Nat Clin Pract Cardiovasc Med. 2007 Apr;4(4):188-9.

Wang CH, Verma S, Hsieh IC, Hung A, Cheng TT, Wang SY, Liu YC, Stanford WL, Weisel RD, Li RK, Cherng WJ. Stem cell factor attenuates vascular smooth muscle apoptosis and increases intimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):540-7.

Brister SJ, Hamdulay Z, Verma S, Maganti M, Buchanan MR. Ethnic diversity: South Asian ethnicity is associated with increased coronary artery bypass grafting mortality. J Thorac Cardiovasc Surg. 2007 Jan;133(1):150-4.


Wang CH, Ting MK, Verma S, Kuo LT, Yang NI, Hsieh IC, Wang SY, Hung A, Cherng WJ. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J. 2006 Dec;152(6):1051.e1-8.

Szmitko PE, Kutryk MJ, Stewart DJ, Strauss MH, Verma S. Endothelial progenitor cell-coated stents under scrutiny. Can J Cardiol. 2006 Nov;22(13):1117-9.

Szmitko PE, Verma S. C-reactive protein and the metabolic syndrome: useful addition to the cardiovascular risk profile? J Cardiometab Syndr. 2006 Winter;1(1):66-9; quiz 70-1.

Gupta M, Singh N, Verma S. South Asians and cardiovascular risk: What clinicians should know. Circulation. 2006; 113:924-929.